Appointment of Independent Non-Executive Director
09/01/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230109:nRSI0106Ma&default-theme=true
RNS Number : 0106M Instem plc 09 January 2023
Instem plc
("Instem", the "Group" or the "Company")
Appointment of Independent Non-Executive Director
Instem plc (AIM: INS), a leading provider of IT solutions to the global life
sciences market, announces that it has appointed Mary Dolson as an Independent
Non-Executive Director to the Board and Chair of the Audit Committee,
effective 9 January 2023. Mary will also join the Remuneration and
Nomination Committees immediately upon appointment.
Mary is an expert advisor on regulatory, financial and accounting compliance
issues, with extensive experience advising businesses in the pharmaceutical,
biotech and life science sectors. She is a specialist and experienced advisor
in taking companies through periods of change, from start-up to venture
capital investments to public offerings.
Most recently, Mary was a Non-Executive Director at Nuvelution Pharma Inc
(Boston, USA) between 2019 and 2021, where she consulted as an expert in
finance, modelling, and risk across all phases of the pharmaceutical and
biotech industry.
Mary has spent most of her career in audit and served as a PwC partner in
London for over 20 years, where she became the Global Lead on pharmaceutical
industry accounting and reporting before retiring in 2018. Mary was a founding
member of the 'Pharma Forum', an industry based International Financial
Reporting Standards working group.
Mary served as a Non-Executive Committee Member for the Financial Reporting
Review Panel (UK), a position she held from 2011 until 31 December 2020 (when
it was dissolved). In this role, Mary helped to guide the implementation of
accounting standards, corporate governance, and other reporting codes.
Mary is a Bachelor of Business Accounting graduate of Pace University, Lubin
School of Business, New York, and a Certified Public Accountant (CPA) in the
State of New York.
Revised Board and Committee Membership
Effective with Mary's appointment, Board committee membership has been revised
as follows:
Audit Committee Remuneration Committee Nomination Committee
· Mary Dolson - Chair · Riaz Bandali - Chair · David Gare - Chair
· Riaz Bandali · Mary Dolson · Mary Dolson
· Mike McGoun · Mike McGoun · Riaz Bandali
· Mike McGoun
Committee membership will be reviewed periodically in line with good
governance practice.
Following completion of Mary's initial on-boarding process, David Sherwin
(Non-executive Director) has indicated that he intends to retire from the
Board, with a confirmatory announcement to be made at that time.
Strengthened Team
The Company is also pleased to announce that John Alarcon has been appointed
into a full-time employee position as Vice President of Strategic Partnerships
and Vice President of US Finance. John joined Instem on a contract basis in
2019 and led the buy-side due diligence, modelling, and integration efforts on
the d-Wise acquisition, and supported on those of The Edge and PDS Life
Sciences. More recently he took responsibility as Interim Controller for
Instem's Clinical Trial Acceleration business unit. John draws on over a
decade's finance experience with VC backed technology companies and prior to
joining Instem was running his own consulting practice.
In his new role based in the US, John will head Instem's US Finance team and
will report to Chief Financial Officer, Nigel Goldsmith.
Commenting on the appointments, Phil Reason, CEO of Instem, said: "We are
delighted to welcome Mary to the Board of Instem as an Independent
Non-Executive Director. To have the support of someone with such unequivocal
financial and industry expertise will be invaluable in helping the Company and
Board realise its aspirations, and her joining the Board is undoubtedly a
testament to where Instem has progressed to today. Mary's experience is
comprehensive, and she is perfectly suited, having worked extensively in the
UK and US, to advise on the challenges and opportunities that we encounter.
"Equally, we are very happy to have John move into his new role. John's
support was central to the acquisition of d-Wise and his appointment
highlights the Company's capability to successfully integrate new businesses."
Further disclosures pursuant to Schedule Two, paragraph (g) of the AIM Rules
for Companies:
Mary Ruth Dolson (formerly known as Hines), aged 63, has no current
directorships and has previously been a director of the following companies
within the past five years:
· Nuvelution Pharma, Inc
· Tuckerbox Consultants Limited
Mary has no beneficial interest in the shares of the Company.
There is no other information required to be disclosed pursuant to Schedule
Two, paragraph (g) of the AIM Rules for Companies.
For further information, please contact:
Instem plc Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Peter Steel
Alex Bond
Stifel Nicolaus Europe Limited (Joint Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Richard Short
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
Joe Walker
About Instem
Instem is a leading provider of IT solutions & services to the life
sciences market delivering compelling solutions for Study Management,
Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based
Insight Generation.
Instem solutions are in use by over 700 customers worldwide, including all of
the largest 25 pharmaceutical companies, enabling clients to bring life
enhancing products to market faster. Instem's portfolio of software solutions
increases client productivity by automating study-related processes while
offering the unique ability to generate new knowledge through the extraction
and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development
value chain, from discovery through to market launch. Management estimate that
over 50% of all drugs on the market have been through some part of Instem's
platform during their development.
To learn more about Instem solutions and its mission, please
visit www.instem.com (http://www.instem.com/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BOAEAPFXEEDDEEA